- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Rheumatoid arthritis
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 568KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 96KB)
Infliximab – November 2022
Infliximab: Solution for injection 120 mg in 1 mL pre-filled pen, Solution for injection 120 mg in 1 mL pre-filled syringe; Remsima® SC
Last updated
3 March 2023